Trials / Completed
CompletedNCT02982707
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | Single oral dose |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2018-09-28
- Completion
- 2018-09-28
- First posted
- 2016-12-05
- Last updated
- 2018-11-14
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02982707. Inclusion in this directory is not an endorsement.